- ISIN
- US48576U1060
- CUSIP
- 48576U106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 6, 2013
Highlights
- Market Cap
- $228.12M
- Enterprise Value
- $155.95M
- EPS (TTM)
- -$13.00
- Total Revenue (TTM)
- $151.12M
- Gross Profit (TTM)
- $145.13M
- EBITDA (TTM)
- -$93.05M
- Year Range
- $3.65 - $10.99
- Target Price
- $17.25
- ROA (TTM)
- -148.36%
- ROE (TTM)
- 73.39%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KPTI Performance Chart
Karyopharm Therapeutics Inc. (KPTI) is up 25.4% since the beginning of the year. At $9 per share, KPTI is trading 16.0% below its 52-week high of $11. Investors who bought $1,000 worth of KPTI shares 5 years ago would now be looking at an investment worth $67.
Loading charts...
Returns By Period
Karyopharm Therapeutics Inc. (KPTI) has returned 25.41% so far this year and 124.03% over the past 12 months. Over the last ten years, KPTI has returned -23.74% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
Karyopharm Therapeutics Inc.
- 1D
- -6.01%
- 1M
- 5.25%
- YTD
- 25.41%
- 6M
- 72.20%
- 1Y
- 124.03%
- 3Y*
- -35.19%
- 5Y*
- -41.84%
- 10Y*
- -23.74%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
KPTI Monthly Returns History
Based on dividend-adjusted daily data since Nov 6, 2013, KPTI's average daily return is +0.04%, while the average monthly return is +0.89%. At this rate, an investment would double in approximately 6.5 years.
Historically, 47% of months were positive and 53% were negative. The best month was Aug 2025 with a return of +86.6%, while the worst month was Jan 2016 at -53.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, KPTI closed higher 48% of trading days. The best single day was Jun 13, 2014 with a return of +93.5%, while the worst single day was Feb 22, 2019 at -43.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.41% | 44.33% | -40.81% | 49.19% | 9.51% | 1.43% | 25.41% | ||||||
| 2025 | -8.01% | -14.80% | -52.96% | 80.48% | -37.78% | 2.62% | -11.60% | 86.61% | -8.02% | -11.31% | -3.10% | 30.96% | -27.45% |
| 2024 | -13.24% | 54.56% | 30.17% | -31.79% | -5.91% | -10.47% | 13.97% | -23.12% | 9.18% | 19.25% | -14.63% | -19.96% | -21.82% |
| 2023 | -2.94% | -8.48% | 28.81% | -7.97% | -36.87% | -20.80% | 0.56% | -28.89% | 4.69% | -35.07% | -11.49% | 12.34% | -74.56% |
| 2022 | 38.41% | 16.07% | -28.65% | -17.23% | 2.95% | -28.18% | -5.76% | 19.06% | 7.91% | -12.82% | 11.13% | -35.73% | -47.12% |
| 2021 | -1.61% | -9.26% | -23.88% | -11.22% | -0.64% | 11.21% | -19.28% | -30.37% | 0.34% | -6.19% | 27.29% | -7.48% | -58.46% |
Benchmark Metrics
Karyopharm Therapeutics Inc. has an annualized alpha of -7.82%, beta of 1.47, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since November 07, 2013.
- This stock participated in 164.87% of S&P 500 Index downside but only 9.62% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.82%
- Beta
- 1.47
- R²
- 0.08
- Upside Capture
- 9.62%
- Downside Capture
- 164.87%
Return for Risk
Risk / Return Rank
KPTI ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and compare them to S&P 500 Index.
| KPTI | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.33 | 2.39 | -1.06 |
Sortino ratioReturn per unit of downside risk | 2.29 | 3.25 | -0.97 |
Omega ratioGain probability vs. loss probability | 1.26 | 1.43 | -0.17 |
Calmar ratioReturn relative to maximum drawdown | 2.58 | 3.11 | -0.53 |
Martin ratioReturn relative to average drawdown | 6.39 | 14.38 | -7.99 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Karyopharm Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Karyopharm Therapeutics Inc. was 99.50%, occurring on Apr 1, 2025. The portfolio has not yet recovered.
The current Karyopharm Therapeutics Inc. drawdown is 98.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.50%Apr 2025 | 10y 9mo | — | 11y 11moJun 2014 - now |
2014 bear market2014 | -43.74%Jun 2014 | 3mo 7d | 1d | 3mo 8dMar 2014 - Jun 2014 |
2014 correction2014 | -10.42%Jan 2014 | 21d | 2d | 23dDec 2013 - Jan 2014 |
2014 pullback2014 | -9.08%Feb 2014 | 2d | 7d | 9dFeb 2014 - Feb 2014 |
2014 pullback2014 | -8.83%Mar 2014 | 0s | 1d | 1dMar 2014 - Mar 2014 |
Drawdown Indicators
| KPTI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.50% | -56.78% | -42.72% |
Max Drawdown (1Y)Largest decline over 1 year | -48.36% | -9.10% | -39.26% |
Max Drawdown (3Y)Largest decline over 3 years | -90.08% | -18.90% | -71.18% |
Max Drawdown (5Y)Largest decline over 5 years | -98.36% | -25.43% | -72.93% |
Max Drawdown (10Y)Largest decline over 10 years | -99.15% | -33.92% | -65.23% |
Current DrawdownCurrent decline from peak | -98.69% | 0.00% | -98.69% |
Average DrawdownAverage peak-to-trough decline | -75.25% | -10.72% | -64.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.48% | 1.97% | +17.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Karyopharm Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Karyopharm Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KPTI relative to other companies in the Biotechnology industry. Currently, KPTI has a P/S ratio of 0.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KPTI
Add Karyopharm Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KPTI